1、 胡晋卿,肖桃,朱秀清,等.奥氮平联合舍曲林对于奥氮平血药浓度的影响研究[J].中国医院用药评价与分析,2023,23(3):264-267. 胡晋卿,肖桃,朱秀清,等.奥氮平联合舍曲林对于奥氮平血药浓度的影响研究[J].中国医院用药评价与分析,2023,23(3):264-267.
2、 张冬阳,宋明芬,闫盼,等.氟伏沙明和CYP1A2~*1F基因多态性对血清奥氮平浓度的影响[J].中国现代应用药学,2020,37(5):591-594. 张冬阳,宋明芬,闫盼,等.氟伏沙明和CYP1A2~*1F基因多态性对血清奥氮平浓度的影响[J].中国现代应用药学,2020,37(5):591-594.
3、 DJORDJEVIC N,RADMANOVIC B,CUKIC J,et al.Cigarette smoking and heavy coffee consumption affecting response to olanzapine:The role of genetic polymorphism[J].World J Biol Psychiatry,2020,21(1):29-52. DJORDJEVIC N,RADMANOVIC B,CUKIC J,et al.Cigarette smoking and heavy coffee consumption affecting response to olanzapine:The role of genetic polymorphism[J].World J Biol Psychiatry,2020,21(1):29-52.
4、 FEKETE F,MENUS á,TóTH K,et al.CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients[J].Sci Rep,2023,13(1):18507. FEKETE F,MENUS á,TóTH K,et al.CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients[J].Sci Rep,2023,13(1):18507.
5、 ROJAS-MACETAS A,MEDALLA-GARRO G,SARAVIA M,et al.Potential polymorphic CYP1A2 and CYP2D6-mediated pharmacokinetic interactions between risperidone or olanzapine and selected drugs intended to treat COVID-19[J].Drug Metab Bioanal Lett,2022. ROJAS-MACETAS A,MEDALLA-GARRO G,SARAVIA M,et al.Potential polymorphic CYP1A2 and CYP2D6-mediated pharmacokinetic interactions between risperidone or olanzapine and selected drugs intended to treat COVID-19[J].Drug Metab Bioanal Lett,2022.
6、 CITROME L,STAUFFER V L,CHEN L,et al.Olanzapine plasma concentrations after treatment with 10,20,and 40 mg/d in patients with schizophrenia:An analysis of correlations with efficacy,weight gain,and prolactin concentration[J].J Clin Psychopharmacol,2009,29(3):278-283. CITROME L,STAUFFER V L,CHEN L,et al.Olanzapine plasma concentrations after treatment with 10,20,and 40 mg/d in patients with schizophrenia:An analysis of correlations with efficacy,weight gain,and prolactin concentration[J].J Clin Psychopharmacol,2009,29(3):278-283.
7、 SUN L,YAGODA S,DU Y,et al.Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet[J].Drug Des Devel Ther,2019(13):2941-2955. SUN L,YAGODA S,DU Y,et al.Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet[J].Drug Des Devel Ther,2019(13):2941-2955.
8、 AN H,FAN H,CHEN S,et al.Effects of dose,age,sex,body weight,and smoking on plasma concentrations of olanzapine and N-desmethyl olanzapine in inpatients with schizophrenia[J].J Clin Psychopharmacol,2021,41(3):255-259. AN H,FAN H,CHEN S,et al.Effects of dose,age,sex,body weight,and smoking on plasma concentrations of olanzapine and N-desmethyl olanzapine in inpatients with schizophrenia[J].J Clin Psychopharmacol,2021,41(3):255-259.
9、 PATEL M X,BOWSKILL S,COUCHMAN L,et al.Plasma olanzapine in relation to prescribed dose and other factors:Data from a therapeutic drug monitoring service,1999-2009[J].J Clin Psychopharmacol,2011,31(4):411-417. PATEL M X,BOWSKILL S,COUCHMAN L,et al.Plasma olanzapine in relation to prescribed dose and other factors:Data from a therapeutic drug monitoring service,1999-2009[J].J Clin Psychopharmacol,2011,31(4):411-417.
10、 钟璐莲,陈政,彭陈陈,等.阿立哌唑血药浓度/剂量比影响因素分析及临床应用[J].广州医药,2022,53(3):100-103. 钟璐莲,陈政,彭陈陈,等.阿立哌唑血药浓度/剂量比影响因素分析及临床应用[J].广州医药,2022,53(3):100-103.
11、 TSIOKOU V,KILINDRIS T,BEGAS E,et al.Altered activity of xenobiotic detoxifying enzymes at menopause-A cross-sectional study[J].Environ Res,2020(182):109074. TSIOKOU V,KILINDRIS T,BEGAS E,et al.Altered activity of xenobiotic detoxifying enzymes at menopause-A cross-sectional study[J].Environ Res,2020(182):109074.
12、 DING J,ZHANG Y,ZHANG Y,et al.Effects of age,sex,and comedication on the plasma concentrations of olanzapine in Chinese patients with schizophrenia based on therapeutic drug monitoring data[J].J Clin Psychopharmacol,2022,42(6):552-559. DING J,ZHANG Y,ZHANG Y,et al.Effects of age,sex,and comedication on the plasma concentrations of olanzapine in Chinese patients with schizophrenia based on therapeutic drug monitoring data[J].J Clin Psychopharmacol,2022,42(6):552-559.
13、 张巧真,黄敏芳,宋伟明.4969例奥氮平血药浓度日常检测及药师干预分析[J].现代实用医学,2018,30(4):492-493. 张巧真,黄敏芳,宋伟明.4969例奥氮平血药浓度日常检测及药师干预分析[J].现代实用医学,2018,30(4):492-493.
14、 闫盼,宋明芬,王晟东,等.CYP1A2基因多态性对精神分裂症患者奥氮平血药浓度的影响[J].中华全科医学,2020,18(11):1851-1853,1939. 闫盼,宋明芬,王晟东,等.CYP1A2基因多态性对精神分裂症患者奥氮平血药浓度的影响[J].中华全科医学,2020,18(11):1851-1853,1939.
15、 DENG S H,WANG Z Z,LU H Y,et al.A retrospective analysis of steady-state olanzapine concentrations in Chinese patients using therapeutic drug monitoring:Effects of valproate and other factors[J].Ther Drug Monit,2020,42(4):636-642. DENG S H,WANG Z Z,LU H Y,et al.A retrospective analysis of steady-state olanzapine concentrations in Chinese patients using therapeutic drug monitoring:Effects of valproate and other factors[J].Ther Drug Monit,2020,42(4):636-642.
16、 肖桃. 基于群体药代动力学建模与仿真技术实施奥氮平在特殊人群的个体化用药研究[D].广州:广州医科大学,2022. 肖桃. 基于群体药代动力学建模与仿真技术实施奥氮平在特殊人群的个体化用药研究[D].广州:广州医科大学,2022.
17、 CATAFAU A M,PENENGO M M,NUCCI G,et al.Pharmacokinetics and time-course of D(2)receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients[J].J Psychopharmacol,2008,22(8):882-894. CATAFAU A M,PENENGO M M,NUCCI G,et al.Pharmacokinetics and time-course of D(2)receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients[J].J Psychopharmacol,2008,22(8):882-894.
18、 PILLA R V,KOZIELSKA M,SULEIMAN A A,et al.Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I:The use of PANSS total score and clinical utility[J].Schizophr Res,2013,146(1-3):144-152. PILLA R V,KOZIELSKA M,SULEIMAN A A,et al.Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I:The use of PANSS total score and clinical utility[J].Schizophr Res,2013,146(1-3):144-152.
19、 WANG X,HAN Y,ZHOU H,et al.Prediction of steady-state plasma concentrations of olanzapine in Chinese Han in patients based on a retrospective population pharmacokinetic model[J].2021,20(11):2433-2441. WANG X,HAN Y,ZHOU H,et al.Prediction of steady-state plasma concentrations of olanzapine in Chinese Han in patients based on a retrospective population pharmacokinetic model[J].2021,20(11):2433-2441.
20、 BIGOS K L,POLLOCK B G,COLEY K C,et al.Sex,race,and smoking impact olanzapine exposure[J].J Clin Pharmacol,2008,48(2):157-165. BIGOS K L,POLLOCK B G,COLEY K C,et al.Sex,race,and smoking impact olanzapine exposure[J].J Clin Pharmacol,2008,48(2):157-165.
21、 XIAO T,WANG Z,LI G,et al.What to do about missed doses? A retrospective study of olanzapine in the elderly[J].Drug Des Devel Ther,2021(15):3411-3423. XIAO T,WANG Z,LI G,et al.What to do about missed doses? A retrospective study of olanzapine in the elderly[J].Drug Des Devel Ther,2021(15):3411-3423.
22、 杜萍,李鹏飞,刘洪川,等.奥氮平在中国健康人体中群体药代动力学研究[J].中国临床药理学杂志,2019,35(15):1652-1656. 杜萍,李鹏飞,刘洪川,等.奥氮平在中国健康人体中群体药代动力学研究[J].中国临床药理学杂志,2019,35(15):1652-1656.
23、 YIN A,SHANG D,WEN Y,et al.Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis[J].Eur J Clin Pharmacol,2016,72(8):933-944. YIN A,SHANG D,WEN Y,et al.Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis[J].Eur J Clin Pharmacol,2016,72(8):933-944.
24、 ZANG Y N,DONG F,LI A N,et al.The impact of smoking,sex,infection,and comedication administration on oral olanzapine:A population pharmacokinetic model in Chinese psychiatric patients[J].Eur J Drug Metab Pharmacokinet,2021,46(3):353-371. ZANG Y N,DONG F,LI A N,et al.The impact of smoking,sex,infection,and comedication administration on oral olanzapine:A population pharmacokinetic model in Chinese psychiatric patients[J].Eur J Drug Metab Pharmacokinet,2021,46(3):353-371.
25、 DAVIES S J,MULSANT B H,FLINT A J,et al.The impact of sertraline co-administration on the pharmacokinetics of olanzapine:A population pharmacokinetic analysis of the STOP-PD[J].Clin Pharmacokinet,2015,54(11):1161-1168. DAVIES S J,MULSANT B H,FLINT A J,et al.The impact of sertraline co-administration on the pharmacokinetics of olanzapine:A population pharmacokinetic analysis of the STOP-PD[J].Clin Pharmacokinet,2015,54(11):1161-1168.
26、 LOBO E D,ROBERTSON-PLOUCH C,QUINLAN T,et al.Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder:A population pharmacokinetic model[J].Paediatr Drugs,2010,12(3):201-211. LOBO E D,ROBERTSON-PLOUCH C,QUINLAN T,et al.Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder:A population pharmacokinetic model[J].Paediatr Drugs,2010,12(3):201-211.
27、 XIAO T,HU J Q,LIU S J,et al.Population pharmacokinetics and dosing optimization of olanzapine in Chinese paediatric patients:Based on the impact of sex and concomitant valproate on clearance[J].J Clin Pharm Ther,2022,47(11):1811-1819. XIAO T,HU J Q,LIU S J,et al.Population pharmacokinetics and dosing optimization of olanzapine in Chinese paediatric patients:Based on the impact of sex and concomitant valproate on clearance[J].J Clin Pharm Ther,2022,47(11):1811-1819.
28、 SUN L,MILLS R,SADLER B M,et al.Population pharmacokinetics of olanzapine and samidorphan when administered in combination in healthy subjects and patients with schizophrenia[J].J Clin Pharmacol,2021,61(11):1430-1441. SUN L,MILLS R,SADLER B M,et al.Population pharmacokinetics of olanzapine and samidorphan when administered in combination in healthy subjects and patients with schizophrenia[J].J Clin Pharmacol,2021,61(11):1430-1441.
29、 LI A,JI S,YUE W,et al.Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia[J].BMJ Open,2018,8(8):e020070. LI A,JI S,YUE W,et al.Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia[J].BMJ Open,2018,8(8):e020070.
30、 MAHARAJ A R,WU H,ZIMMERMAN K O,et al.Population pharmacokinetics of olanzapine in children[J].Br J Clin Pharmacol,2021,87(2):542-554. MAHARAJ A R,WU H,ZIMMERMAN K O,et al.Population pharmacokinetics of olanzapine in children[J].Br J Clin Pharmacol,2021,87(2):542-554.
31、 HIEMKE C,BERGEMANN N,CLEMENT H W,et al.Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology:Update 2017[J].Pharmacopsychiatry,2018,51(1-2):e1. HIEMKE C,BERGEMANN N,CLEMENT H W,et al.Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology:Update 2017[J].Pharmacopsychiatry,2018,51(1-2):e1.
32、 MOSCHNY N,HEFNER G,GROHMANN R,et al.Therapeutic drug monitoring of second-and third-generation antipsychotic drugs-influence of smoking behavior and inflammation on pharmacokinetics[J].Pharmaceuticals(Basel),2021,14(6):514. MOSCHNY N,HEFNER G,GROHMANN R,et al.Therapeutic drug monitoring of second-and third-generation antipsychotic drugs-influence of smoking behavior and inflammation on pharmacokinetics[J].Pharmaceuticals(Basel),2021,14(6):514.
33、 KOLLER D,ALMENARA S,MEJíA G,et al.Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in a randomised crossover clinical trial in healthy volunteers:Association with pharmacogenetics[J].Adv Ther,2021,38(2):1035-1054. KOLLER D,ALMENARA S,MEJíA G,et al.Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in a randomised crossover clinical trial in healthy volunteers:Association with pharmacogenetics[J].Adv Ther,2021,38(2):1035-1054.
34、 刘昀,古美玲,庄淑丽.基于中国PIM标准分析老年精神疾病住院患者潜在不适当用药现状[J].广州医药,2022,53(3):57-61. 刘昀,古美玲,庄淑丽.基于中国PIM标准分析老年精神疾病住院患者潜在不适当用药现状[J].广州医药,2022,53(3):57-61.
35、 SORIA-CHACARTEGUI P,VILLAPALOS-GARCIA G,ZUBIAUR P,et al.Genetic polymorphisms associated with the pharmacokinetics,pharmacodynamics and adverse effects of olanzapine,aripiprazole and risperidone[J].Front Pharmacol,2021(12):711940. SORIA-CHACARTEGUI P,VILLAPALOS-GARCIA G,ZUBIAUR P,et al.Genetic polymorphisms associated with the pharmacokinetics,pharmacodynamics and adverse effects of olanzapine,aripiprazole and risperidone[J].Front Pharmacol,2021(12):711940.
